Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Allergic rhinitis: market evolution

Nature Reviews Drug Discovery volume 8, pages 271–272 (2009)Cite this article

During the past decade, the market for branded products for allergic rhinitis has come under intense pressure, owing to a combination of over-the-counter (OTC) switches, patent expirations, poorer insurance tiering in the United States and exclusivity challenges. Consequently, this therapeutic area is no longer a priority for many companies (timeline).

Nevertheless, recent market events suggest that allergic rhinitis should still be monitored by drug developers, especially as companies diversify their business models into generics and OTC businesses. For example, for both major drug classes for allergic rhinitis — antihistamines and intranasal steroids (INS) — new products have been launched, major deals have been made and OTC sales have been strong. In addition, the INS class has shown considerable resilience to generic competition and health insurance pressure. This article discusses these market events, highlighting the future potential of the area.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The prevalence of allergic rhinitis is comparable to other major chronic diseases.

References

  1. Therapeutic Categories Outlook. Cowen and Company (September 2008).

  2. Decision Resources, Inc. Immune and Inflammatory Disorders Study #55: Allergic Rhinitis. (Decision Resources, Inc., Waltham, Massachusetts, 2005).

  3. Statistical Fact Sheet — Risk Factors. American Heart Association [online],

  4. High Blood Pressure, Who's at Risk? National Heart Lung and Blood Institute (National Institutes of Health) [online],

Download references

Author information

Authors and Affiliations

  1. Matthew J. Clark and Ryan P. Million are at Trinity Partners, 100 Park Avenue, Suite 1600, New York, New York 10017, USA. rmillion@trinitypartners.com mclark@trinitypartners.com,

    Matthew J. Clark & Ryan P. Million

Authors
  1. Matthew J. Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryan P. Million
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clark, M., Million, R. Allergic rhinitis: market evolution. Nat Rev Drug Discov 8, 271–272 (2009). https://doi.org/10.1038/nrd2762

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2762

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing